Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer SAN FRANCISCO and SUZHOU, China, March 24, 2025 /PRNewswire/ — Innovent Biologics, Inc.… CISION PRNewswireMarch 24, 2025
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates HONG KONG, March 24, 2025 /PRNewswire/ — AIM Vaccine Co., Ltd. (06660.HK),… CISION PRNewswireMarch 24, 2025
Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019 — U.S. IND clearance and revaccination trial initiation supports the differentiated global opportunity… CISION PRNewswireMarch 24, 2025
Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14 EVM14 received U.S. FDA clearance for its IND application, becoming Everest’s first… CISION PRNewswireMarch 24, 2025
CROSSFIRE REBRANDS TO JENSEN HUGHES, EXPANDING ITS FIRE SAFETY AND PERFORMANCE-BASED DESIGN ENGINEERING OFFERINGS AUCKLAND, New Zealand, March 24, 2025 /PRNewswire/ — Jensen Hughes, a global… CISION PRNewswireMarch 24, 2025
BusinessPress ReleaseConfidence among small businesses in Singapore rises Business sentiment among small businesses in Singapore reached a five-year high in… CISION PRNewswireMarch 24, 2025
Hyundai Capital Australia Obtains Its First Credit Rating of 'A-' from S&P Global Ratings SEOUL, South Korea, March 24, 2025 /PRNewswire/ — Hyundai Capital Services ("Hyundai… CISION PRNewswireMarch 24, 2025
Volpara Health Announces BOADICEA Integration and Record ECR 2025 Research Presence CANBERRA, Australia, March 24, 2025 /PRNewswire/ — Volpara Health, a global leader in… CISION PRNewswireMarch 24, 2025
